

NOTICE TO THE BAR

MULTICOUNTY LITIGATION APPLICATION -- NEW JERSEY STATE COURT LITIGATION INVOLVING SINGULAIR

The Supreme Court has received an application pursuant to Directive #02-19, "Multicounty Litigation Guidelines and Criteria for Designation (Revised)," for Multicounty Litigation (MCL) designation of New Jersey state-court litigation against Merck & Co., Inc. and Merck Sharp & Dohme Corp. alleging injuries as a result of the use of the prescription medication Singulair. Singulair is a prescription medication used to treat asthma and allergies.


The MCL application was submitted by counsel for plaintiffs.

Anyone wishing to comment on or object to this application should provide such comments or objections in writing, with relevant supporting documentation, by **October 10, 2021** to:

Hon. Glenn A. Grant
Acting Administrative Director of the Courts
Attention: MCL Application – Singulair
Hughes Justice Complex, P.O. Box 037
Trenton, New Jersey 08625-0037

Comments/objections may also be submitted by email to Comments.mailbox@njcourts.gov.

A copy of the application submitted to the Court is posted with this Notice on the Judiciary's Internet Website at (www.njcourts.gov) in the Multicounty Litigation Information Center <http://www.njcourts.gov/attorneys/mcl/index.html>.



Glenn A. Grant, J.A.D.
Acting Administrative Director of the Courts

Dated: September 7, 2021

Corrected